CYTR Cytrx Dashboard

CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.

Company profile

Ticker

CYTR

Exchange

OTC

Website

www.cytrx.com

CEO

Steven A. Kriegsman

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...

SEC CIK

0000799698

Corporate docs

Articles of Incorporation & Bylaws

IRS number

581642750

CYTR stock data

S&P 500

1M 1Y 2Y 5Y

Press releases

Pro users get this 30m faster

CytRx Notes Orphazyme's Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis

1 Apr 21

CytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S

CytRx Highlights Orphazyme's Momentum Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C

8 Mar 21

Orphazyme Announces the Global Brand Name for Arimoclomol – MIPLYFFA – Ahead of Prospective FDA and EMA Approvals Expanded its Early Access Program for NPC in the U.S. and Europe as Well as Expectation of European

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

24 Mar 21

17 Apr 21

31 Dec 21

Financial summary

Financial statements Chart CYTR financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Cytrx earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	10M	10M	10M	10M	10M	10M
Cash burn (monthly)	866.17K	510.59K	474.26K	569.1K	866.17K	511.68K
Cash used (since last report)	3.09M	1.82M	1.69M	2.03M	3.09M	1.82M
Cash remaining	6.91M	8.18M	8.31M	7.97M	6.91M	8.18M
Runway (months of cash)	8.0	16.0	17.5	14.0	8.0	16.0

Beta Read what these cash burn values mean

Recent insider trades

CYTR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Aug 20	Earl W Brien	Common Stock, par value $0.001 per share	Option exercise	Aquire M	No	No	0.26	150,000	39K	590,247
14 Aug 20	Earl W Brien	Stock Option CytRx Common Stock	Option exercise	Dispose M	No	No	0.26	150,000	39K	300,000
7 Aug 20	Joel K Caldwell	Common Stock, par value $0.001 per share	Payment of exercise	Dispose F	No	No	0.67	174,627	117K	335,373
7 Aug 20	Joel K Caldwell	Common Stock, par value $0.001 per share	Option exercise	Aquire M	No	No	0.26	450,000	117K	510,000
7 Aug 20	Joel K Caldwell	Stock Option CytRx Common Stock	Option exercise	Dispose M	No	No	0.26	450,000	117K	0
7 Aug 20	Louis Ignarro	Common Stock, par value $0.001 per share	Payment of exercise	Dispose F	No	No	0.67	271,642	182K	600,785
7 Aug 20	Louis Ignarro	Common Stock, par value $0.001 per share	Option exercise	Aquire M	No	No	0.26	700,000	182K	872,427
7 Aug 20	Louis Ignarro	Stock Option CytRx Common Stock	Option exercise	Dispose M	No	No	0.26	700,000	182K	0
7 Aug 20	Steven A Kriegsman	Common Stock, par value $0.001 per share	Payment of exercise	Dispose F	No	No	0.67	1,164,179	780K	3,668,038
7 Aug 20	Steven A Kriegsman	Common Stock, par value $0.001 per share	Option exercise	Aquire M	No	No	0.26	3,000,000	780K	4,832,217

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

CYTR institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Celgene • Seagen • Glaxosmithkline • Stemline Therapeutics • Takeda Pharmaceutical

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: antidilutive, approach, authoritative, Celgene, depositary, dividing, endanger, evidenced, German, IBM, jeopardize, lieu, lowest, MIPLYFFA, multiplied, NantKwest, neurodegenerative, possession, recalculated, regular, remotely, subdivision, subscribe, subscription, threshold, today, tradename, virtually

Removed: accrual, acute, allocable, autoimmune, chronic, decreased, depressed, distinction, distinguishing, distributed, Document, Eric, float, fourteen, HTGC, inflammatory, initially, Instruction, investing, joining, Kratz, lender, Linkbase, literature, LLP, Master, opening, originally, planning, prepaid, production, ranged, ratably, remained, represented, representing, retrospective, Schema, Taxonomy, transition, unit, USA, viral, XBRL

From filing 10-K 2020 FY